Vera Zdravkovic -End users and Open access in biomedical science

Loading...

Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

0 comments

Post a comment

    Post a comment
    Embed Video
    Edit your comment Cancel

    Notes on slide 1

    PLoS Medicine je vodeći časopis sa otvorenim pristupom Nedavna ispitivanja sugerišu da se časopisi slobodno dostupni preuzimaju i citiraju sve više. PLoS Medicine is run by a team of experienced professional editors. The professional editors work closely with academic editors and peer reviewers to provide authors with an efficient, fair, and constructive review process. Time-saving presubmission inquiries. It is essential that authors provide a presubmission inquiry, consisting of a referenced abstract and a cover letter, prior to full submission. This allows us to let you know within 48 hours whether the paper is within our scope and whether we will consider the full paper. Read more about the scope of the journal. Your research, put in context. Each research article is accompanied by an Editors’ Summary written to be understandable by all medical professionals, whatever their specialty, and the general public. Unlike other leading publications, we will not totally rewrite your paper to conform to house style. We will, of course, help authors whose first language is not English. In addition, we will not ask you to shorten your paper unnecessarily, although we do require papers to be written concisely No need to order reprints. Our open access license means that anyone can reprint and distribute our content, so long as they credit the author and cite the original source. Commercial publishing companies make huge profits reprinting your work—now you have an alternative Your research has the chance to have a high impact. There are a number of ways of measuring a journal's impact, including the influence it has on health policy, how widely read its papers are, and how frequently the papers are cited by other researchers. For a more information on impact factors see this blog and for wider discussion of impact see the June 2006 Editorial We send out weekly press releases on papers published by PLoS Medicine to ensure that papers have the greatest chance of being covered accurately by the media. PLoS Medicine provides a number of 'Web 2.0' tools to facilitate community evaluation and discourse around published articles. See our guidelines explaining how you can add notes, comments, and ratings to any PLoS Medicine article.

    Favorites, Groups & Events

    Vera Zdravkovic -End users and Open access in biomedical science - Presentation Transcript

    1. KORISNIK I OTVORENI PRISTUP Vera Zdravkovi ć
    2. KORISNIK
      • Ko su korisnici ?
      • Lekari
      • I straživači
      • P redavači
      • Pacijenti/roditelji
      • Otvoreni pristup je posebno neophodan u zemlji kao Srbija
    3.  
    4. ČASOPISI SA SLOBODNIM PRISTUPOM
      • Medicina 314
      • Pedijatrija 43
      • Clinical Pediatric endocrinolgy (Japan)
      • International Journal of Pediatric endocrinology (US)
      • International Journal of Pediatrics (US)
    5. POTREBA ZA INFORMACIJOM
      • U toku dežurstva dobijate poziv za konsultaciju
      • Mlado muško odojče primljeno zbog izmenjenog stanje svesti
      • Laboratorijske analize: nizak Na i visok K
      • Treba da isključite adrenalnu insuficijenciju
      • Ne postoje svi elementi kliničke slike
      • Konsult u jete Pubmed
    6.  
    7.  
    8.  
    9. International Journal of Pediatric Endocrinology Volume 2009 (2009), Article ID 195728, 4 pages doi:10.1155/2009/195728 Case Report Transient Pseudohypoaldosteronism due to Urinary Tract Infection in Infancy: A Report of 4 Cases Radha Nandagopal , 1   Priya Vaidyanathan , 2  and  Paul Kaplowitz 2 1 Inter-Institute Pediatric Endocrinology Training Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA 2 Department of Endocrinology, Children's National Medical Center, Washington, DC 20010, USA Received 5 December 2008; Revised 10 March 2009; Accepted 23 April 2009 Academic Editor: Christa Flueck  Copyright © 2009 Radha Nandagopal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    10. Abstract Hyponatremia with hyperkalemia in infancy is an uncommon but life-threatening occurrence. In the first weeks of life, this scenario is often associated with aldosterone deficiency due to salt-wasting congenital adrenal hyperplasia . However, alternative diagnoses involving inadequate mineralocorticoid secretion or action must be considered, particularly for infants one month of age or older. We report four infants who presented with profound hyponatremia accompanied by urinary tract infection , ultimately leading to the diagnosis of transient pseudohypoaldosteronism. Our cases provide support for the idea that the renal tubular resistance to aldosterone is due to urinary tract infection itself rather than to underlying urinary tract anomalies typically found in these infants. Awareness of this condition is important so that serum aldosterone, urine sodium, and urine cultures may be obtained immediately in any infant presenting with hyponatremia and hyperkalemia in whom a diagnosis of congenital adrenal hyperplasia was not found. Adequate replacement with intravenous saline and antibiotic therapy is sufficient to correct sodium levels over 24–48 hours.
    11. JOŠ JEDNA PRIMENA OA
      • Saopštavanje važnih informacija javnosti
    12. Neželjena dejstva leka
      • I nicijalno lečenje hipertireoize - lekovi
      • Propiltiouracil i metimazolski preparati
      • Poslednjih godina je prijavljeno 1 4 slučajeva insuficijencije jetre kod dece usled primene PTU
      • U registru pacijenata kojima je iz ovog razloga transplantirana jetra postoji 8 dece
    13. ZAKLJUČAK WORKSHOPA ODRŽANOG 2008
      • Considering the above, we believe that PTU should  never  be used as first line treatment in children. PTU use should only be considered in rare circumstances, such as preparation for surgery in a patient allergic to MMI or in pregnancy.
    14. PUBLIKACIJA ZAKLJUČAKA
      • Kako alarmirati javnost
      • S. Rivkees koji ima 140 radova na Pubmedu, u časopisima koji imaju IF i 50 se odlučuje za OA časopis
    15. International Journal of Pediatric Endocrinology Volume 2009 (2009), Article ID 132041, 8 pages doi:10.1155/2009/132041 Commentary Propylthiouracil (PTU) Hepatoxicity in Children and Recommendations for Discontinuation of Use Scott A. Rivkees 1  and  Donald R. Mattison 2 1 Yale Pediatric Thyroid Center, Yale University School of Medicine, New Haven, CT 06520, USA 2 Obstetric and Pediatric Pharmacology Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA Received 5 April 2009; Accepted 7 April 2009  Izveštaj workshop -a koji je održan pod pokroviteljstvom Best Pharmaceuticals for Children Act, oktobra 2008 da bi se procenila bezbednost primene PTU kod dece
    16.  
    17. THE PUBLIC LIBRARY OF SCIENCE (PLOS)
      • Veliki neprofitni izdavač po principu otvorenog pristupa
      • Izdaje 7 časopisa, do kojih je jedan PLoS Medicine
    18. PLOS MEDICINE
      • Široka dostupnost
      • Brze i profesionalne recenzije (peer review)
      • Mogućnost upita pre slanja članka (ogovor u roku od 48h)
      • Brza publikacija, prosečno oko 6 nedelja
      • Izdavačev komentar
      • Author- mo že sam da edituje tekst
      • Nije potrebno naručivati reprinte
      • Mogućnost postizanja velikog impakt faktora
      • Publicitet
      • Beleške, komentari and ocenjivanje
    19. IMPACT FACTOR - METRICS

    + AnaivkoAnaivko, 3 weeks ago

    custom

    120 views, 0 favs, 1 embeds more stats

    Doctor Vera Zdravkovic presented how end users can more

    More info about this document

    © All Rights Reserved

    Go to text version

    • Total Views 120
      • 119 on SlideShare
      • 1 from embeds
    • Comments 0
    • Favorites 0
    • Downloads 0
    Most viewed embeds
    • 1 views on http://scienceblogs.com

    more

    All embeds
    • 1 views on http://scienceblogs.com

    less

    Flagged as inappropriate Flag as inappropriate
    Flag as inappropriate

    Select your reason for flagging this presentation as inappropriate. If needed, use the feedback form to let us know more details.

    Cancel
    File a copyright complaint
    Having problems? Go to our helpdesk?

    Categories